Improper activation of the immune system contributes to a variety of clinical conditions, including autoimmune and allergic diseases as well as solid organ and bone marrow transplantation. One approach to counteract this activation is through adoptive therapy with regulatory T cells (Tregs). Ef orts to manufacture these cells have led to good manufacturing practice-compliant protocols, and Treg products are entering early clinical trials. Here, we report the stance of the European Union Cooperation in Science and Technology Action BM1305, "Action to Focus and Accelerate Cell-based Toleranceinducing Therapies-A FACTT?," which identif es hurdles hindering Treg clinical applications in Europe and provides possible solutions.
ASJC Scopus subject areas